chr16-68245541-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_012320.4(PLA2G15):āc.115C>Gā(p.Pro39Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000253 in 1,583,804 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000099 ( 0 hom., cov: 32)
Exomes š: 0.000017 ( 0 hom. )
Consequence
PLA2G15
NM_012320.4 missense
NM_012320.4 missense
Scores
6
4
9
Clinical Significance
Conservation
PhyloP100: 2.09
Genes affected
PLA2G15 (HGNC:17163): (phospholipase A2 group XV) Lysophospholipases are enzymes that act on biological membranes to regulate the multifunctional lysophospholipids. The protein encoded by this gene hydrolyzes lysophosphatidylcholine to glycerophosphorylcholine and a free fatty acid. This enzyme is present in the plasma and thought to be associated with high-density lipoprotein. A later paper contradicts the function of this gene. It demonstrates that this gene encodes a lysosomal enzyme instead of a lysophospholipase and has both calcium-independent phospholipase A2 and transacylase activities. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PLA2G15 | NM_012320.4 | c.115C>G | p.Pro39Ala | missense_variant | 1/6 | ENST00000219345.10 | |
PLA2G15 | NM_001363551.2 | c.115C>G | p.Pro39Ala | missense_variant | 1/6 | ||
PLA2G15 | XM_011522979.3 | c.115C>G | p.Pro39Ala | missense_variant | 1/7 | ||
PLA2G15 | XM_011522980.4 | c.115C>G | p.Pro39Ala | missense_variant | 1/7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PLA2G15 | ENST00000219345.10 | c.115C>G | p.Pro39Ala | missense_variant | 1/6 | 1 | NM_012320.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000986 AC: 15AN: 152106Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
15
AN:
152106
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000296 AC: 6AN: 202600Hom.: 0 AF XY: 0.0000452 AC XY: 5AN XY: 110700
GnomAD3 exomes
AF:
AC:
6
AN:
202600
Hom.:
AF XY:
AC XY:
5
AN XY:
110700
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000175 AC: 25AN: 1431698Hom.: 0 Cov.: 31 AF XY: 0.0000183 AC XY: 13AN XY: 711242
GnomAD4 exome
AF:
AC:
25
AN:
1431698
Hom.:
Cov.:
31
AF XY:
AC XY:
13
AN XY:
711242
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000986 AC: 15AN: 152106Hom.: 0 Cov.: 32 AF XY: 0.000148 AC XY: 11AN XY: 74294
GnomAD4 genome
AF:
AC:
15
AN:
152106
Hom.:
Cov.:
32
AF XY:
AC XY:
11
AN XY:
74294
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 16, 2023 | The c.115C>G (p.P39A) alteration is located in exon 1 (coding exon 1) of the PLA2G15 gene. This alteration results from a C to G substitution at nucleotide position 115, causing the proline (P) at amino acid position 39 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Benign
DEOGEN2
Benign
.;T;D;T;.;T;T
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T;T;T;T;T;T
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
N;.;N;.;.;.;.
MutationTaster
Benign
D;D;N;N
PrimateAI
Uncertain
T
PROVEAN
Benign
N;D;D;D;D;N;D
REVEL
Pathogenic
Sift
Pathogenic
D;D;D;D;D;T;D
Sift4G
Pathogenic
D;D;D;D;D;D;D
Polyphen
1.0
.;.;D;.;D;D;.
Vest4
MutPred
Loss of catalytic residue at P38 (P = 0.0131);Loss of catalytic residue at P38 (P = 0.0131);Loss of catalytic residue at P38 (P = 0.0131);Loss of catalytic residue at P38 (P = 0.0131);Loss of catalytic residue at P38 (P = 0.0131);Loss of catalytic residue at P38 (P = 0.0131);Loss of catalytic residue at P38 (P = 0.0131);
MVP
MPC
0.46
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at